Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...